1. Search Result
Search Result
Results for "

tribbles pseudokinase 1 (TRIB1)

" in MedChemExpress (MCE) Product Catalog:

13

Inhibitors & Agonists

4

Recombinant Proteins

1

Isotope-Labeled Compounds

1

Antibodies

3

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-123494

    CaMK Cardiovascular Disease Neurological Disease
    BRD0418 is a diversity-oriented synthesis (DOS) molecule that regulates the expression of tribbles pseudokinase 1. BRD0418 has the effect of causing hot lipoprotein metabolism from fat production to clearance. BRD0418 can be used in the study of coronary artery disease (CAD) [1].
    BRD0418
  • HY-18710

    IKK JAK Inflammation/Immunology
    BMS-066 is an IKKβ/Tyk2 pseudokinase inhibitor, with IC50s of 9 nM and 72 nM, respectively.
    BMS-066
  • HY-141676

    EGFR Others
    HyT36 is a low molecular weight hydrophobic tag that promotes the degradation of fusion protein and pseudokinase Her3 [1] .
    HyT36
  • HY-156466

    STAT Interleukin Related IFNAR Inflammation/Immunology
    QL-1200186 is a selective, orally active, allosteric inhibitor targeting the tyrosine kinase TYK2 pseudokinase domain JH2 (IC50=0.06 nM, TYK2 JH2), with 164-fold selectivity over TYK1 JH2 (IC50=9.85 nM,TYK1 JH2). QL-1200186 first stabilizes the TYK2 JH2 conformation, inhibits the activity of the JH1 catalytic domain, and blocks the IFNα, IL-12/IL-23-mediated JAK-STAT signaling pathway. QL-1200186 can inhibit the production of Th1/Th17 cell-related cytokines (such as IFNγ, IL-23), reduce immune cell activation, and has no significant effect on JAK1/2/3 kinase activity. QL-1200186 can significantly improve skin inflammation in the Imiquimod (HY-B0180)-induced psoriasis mouse model and reduce the Psoriasis Area and Severity Index (PASI) score. QL-1200186 can be used in the study of autoimmune diseases such as psoriasis and systemic lupus erythematosus (SLE) [1].
    QL-1200186
  • HY-112292A
    GW806742X hydrochloride
    20+ Cited Publications

    Mixed Lineage Kinase VEGFR Cancer
    GW806742X hydrochloride, an ATP mimetic and a potent MLKL (Mixed Lineage Kinase Domain-Like protein) inhibitor, binds the MLKL pseudokinase domain with a Kd of 9.3 μM. GW806742X hydrochloride has activity against VEGFR2 (IC50=2 nM). GW806742X hydrochloride retards MLKL membrane translocation and inhibits necroptosis [1] .
    GW806742X hydrochloride
  • HY-112292
    GW806742X
    20+ Cited Publications

    Mixed Lineage Kinase VEGFR Others
    GW806742X, an ATP mimetic and a potent MLKL (Mixed Lineage Kinase Domain-Like protein) inhibitor, binds the MLKL pseudokinase domain with a Kd of 9.3 μM. GW806742X has activity against VEGFR2 (IC50=2 nM). GW806742X retards MLKL membrane translocation and inhibits necroptosis [1] .
    GW806742X
  • HY-RS15015

    Small Interfering RNA (siRNA) Others

    TRIB1 Human Pre-designed siRNA Set A contains three designed siRNAs for TRIB1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    TRIB1 Human Pre-designed siRNA Set A
    TRIB1 Human Pre-designed siRNA Set A
  • HY-RS29392

    Small Interfering RNA (siRNA) Others
    Trib1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Trib1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Trib1 Rat Pre-designed siRNA Set A
    Trib1 Rat Pre-designed siRNA Set A
  • HY-RS22878

    Small Interfering RNA (siRNA) Others

    Trib1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Trib1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Trib1 Mouse Pre-designed siRNA Set A
    Trib1 Mouse Pre-designed siRNA Set A
  • HY-18709

    JAK Inflammation/Immunology
    Tyk2-IN-3 is a Tyk2 pseudokinase inhibitor, with an IC50 of 485 nM.
    Tyk2-IN-3
  • HY-148366

    Mixed Lineage Kinase RIP kinase CDK Cancer
    NecroIr2 is an iridium(III) complex, serves as necroptosis inducers in Cisplatin (HY-17394)-resistant lung cancer cells (A549R). NecroIr2 selectively accumulates in mitochondria, leading to oxidative stress and loss of mitochondrial membrane potential (MMP). NecroIr2 activates receptor-interacting serine-threonine kinase 3 (RIPK3) and mixed lineage kinase domain-like pseudokinase (MLKL), and regulates CDK4 expression [1].
    NecroIr2
  • HY-117287
    Deucravacitinib
    Maximum Cited Publications
    31 Publications Verification

    BMS-986165

    JAK Interleukin Related IFNAR Isotope-Labeled Compounds Inflammation/Immunology
    Deucravacitinib (BMS-986165) is a highly selective, orally bioavailable allosteric TYK2 inhibitor for the treatment of autoimmune diseases, which selectively binds to TYK2 pseudokinase (JH2) domain (IC50=1.0 nM) and blocks receptor-mediated Tyk2 activation by stabilizing the regulatory JH2 domain. Deucravacitinib inhibits IL-12/23 and type I IFN pathways. Deucravacitinib, the FDA's world first de novo deuterium, is available for study in moderate to severe plaque psoriasis [1] .
    Deucravacitinib
  • HY-170995

    PROTACs ROR Apoptosis Cancer
    PROTAC ROR1 degrader-1 (Compound 11d) is a PROTAC degrader for pseudokinase ROR1 that degrades ROR1 in NSCLC cells with a DC50s of 40-80 nM. PROTAC ROR1 degrader-1 causes the cleavage of PARP and induces apoptosis in NCI-H23 [1]. (Pink: ligand for target protein ROR1 ligand-1 (HY-170996); Black: linker (HY-W014787); Blue: ligand for VHL E3 ligase (S,R,S)-AHPC (HY-125845))
    PROTAC ROR1 degrader-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: